Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELESCOPE: Neoadjuvant pembrolizumab + carboplatin + paclitaxel for stage I triple-negative breast cancer
2024-513511-27-00Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by MEDSIR. Primary endpoint: Pathologic complete response in breast and lymph nodes (overall population). Started Apr 2025; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-513511-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513511-27-00.